Study to Determine the Safety and the Efficacy of Fasinumab Compared to Placebo and Nonsteroidal Anti-inflammatory Drugs (NSAIDs) for Treatment of Adults With Pain From Osteoarthritis of the Knee or Hip (FACT OA2)

Regeneron Pharmaceuticals logo

Regeneron Pharmaceuticals

Status and phase

Completed
Phase 3

Conditions

Osteoarthritis, Hip
Osteoarthritis, Knee

Treatments

Drug: Matching placebo
Other: Celecoxib
Drug: Fasinumab
Other: Diclofenac

Study type

Interventional

Funder types

Industry

Identifiers

NCT03304379
R475-OA-1688
2017-001702-15 (EudraCT Number)

Details and patient eligibility

About

The primary objective of the study is to evaluate the efficacy of fasinumab compared to placebo, when administered for up to 24 weeks in patients with pain due to osteoarthritis (OA) of the knee or hip. The secondary objectives of the study are: To evaluate the efficacy of fasinumab compared to non-steroidal anti-inflammatory drugs (NSAID)s, when administered for up to 24 weeks in patients with pain due to OA of the knee or hip To assess the safety and tolerability of fasinumab compared to placebo and compared to NSAIDs, when administered for up to 24 weeks in patients with pain due to OA of the knee or hip

Enrollment

1,650 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Key Inclusion Criteria (additional criteria may apply at screening):

  • A clinical diagnosis of osteoarthritis (OA) of the knee or hip based on the American College of Rheumatology criteria with radiologic evidence of OA (K-L score ≥2 for the index joint) at the screening visit.
  • Willing to discontinue current pain medications and to adhere to study requirements for rescue treatments (acetaminophen/paracetamol to be taken as needed with a maximum daily dose of 2500 mg [countries where 500 mg strength tablets/capsules are available] or 2600 mg [countries where 325 mg strength tablets/capsules are available])
  • A history of at least 12 weeks of inadequate pain relief or intolerance to analgesics used for pain due to OA of the knee or hip
  • Currently using a stable dose of NSAID
  • Willing to discontinue glucosamine sulfate and chondroitin sulfate treatments during the 24 weeks of treatment

Key Exclusion Criteria (additional criteria may apply at screening):

  • Non-compliance with the numeric rating scale (NRS) recording during the pre-randomization period
  • History or presence at the screening visit of non-OA inflammatory joint disease, Paget's disease of the spine, pelvis or femur, neuropathic disorders, multiple sclerosis, fibromyalgia, tumors or infections of the spinal cord, or renal osteodystrophy
  • History or presence on imaging of arthropathy, hip or knee dislocation, extensive subchondral cysts, evidence of severe structural damage, bone collapse, or primary metastatic tumor with the exception of chondromas or pathologic fractures
  • Trauma to the index joint within 3 months prior to the screening visit
  • Signs or symptoms of carpal tunnel syndrome within 6 months of screening
  • Patient is not a candidate for magnetic resonance imaging (MRI)
  • Is scheduled for a JR surgery to be performed during the study period or who would be unwilling or unable to undergo JR surgery if needed
  • History or presence at the screening visit of autonomic or diabetic neuropathy, or other peripheral neuropathy, including reflex sympathetic dystrophy
  • Evidence of autonomic neuropathy as defined in the schedule of assessments (SoAs)
  • History or diagnosis of chronic autonomic failure syndrome including pure autonomic failure, multiple system atrophy
  • Use of systemic corticosteroids within 30 days prior to the screening visit. Intra-articular corticosteroids in the index joint within 12 weeks prior to the screening visit, or to any other joint within 30 days prior to the screening visit
  • Exposure to an anti-NGF antibody prior to the screening visit or known sensitivity or intolerance to anti-NGF antibodies
  • Women of childbearing potential who are unwilling to practice highly effective contraception prior to the start of the first treatment, during the study, and for at least 20 weeks after the last dose

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Triple Blind

1,650 participants in 4 patient groups

Dosing regimen 1
Experimental group
Treatment:
Drug: Fasinumab
Drug: Matching placebo
Dosing regimen 2
Experimental group
Treatment:
Other: Diclofenac
Drug: Matching placebo
Dosing regimen 3
Experimental group
Treatment:
Other: Celecoxib
Drug: Matching placebo
Dosing regimen 4
Experimental group
Treatment:
Drug: Matching placebo

Trial documents
2

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems